JAK2-V617F mutation among blood donors: A meta-analysis.

Abstract excerpt

OBJECTIVES: To systematically review evidence on the prevalence of the JAK2V617F (JAK2) mutation and polycythemia vera (PV) among all blood donors, focusing on those with elevated hematocrit. Although blood donors are generally healthy, considering a preclinical stage of myeloproliferative neoplasm, especially in those with polycythemia, is crucial. Evidence on managing these donors is limited. METHODS: We...

Topics

Join the communities discussing this publication.

• Mutation
• Polycythemia
• Hematocrit
• Janus Kinase 2
• Blood Donors
• Polycythemia Vera